Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press32410.17650/1994-4098-2009-0-3-4-101-107GYNECOLOGY. TREATMENTГИНЕКОЛОГИЯ. ЛЕЧЕНИЕMANAGEMENT IN EARLY OVARIAN CANCER: STANDARDS AND UNSOLVED PROBLEMSСТАНДАРТЫ И НЕРЕШЕННЫЕ ВОПРОСЫ В ЛЕЧЕНИИ РАННЕГО РАКА ЯИЧНИКОВKormoshN. G.КормошН. Г.
Russian Federation
nkormosh@hotmail.comLaktionovK. P.ЛактионовК. П.
Russian Federation
KerzhkovskayaN. S.КержковскаяН. С.
Russian Federation
Research Institute of Clinical Oncology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowНИИ клинической онкологии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва101120093-410110715092014150920142009https://ojrs.abvpress.ru/ojrs/article/view/324

The appropriate management of early-stage ovarian carcinoma is controversial. The literature has been analyzed to find answers to the following questions: how to make an early diagnosis of ovarian cancer and to minimize the treatment in order to avoid complica- tions and toxicity without any harm to health and to increase therapeutic effectiveness. The use of the current noninvasive techniques (positron emission tomography, magnetic resonance imaging) is shown to considerably improve the diagnostic estimation of the extent of a tumor. This fact and deeper knowledge of prognostic factors will allow us to optimize and individualize treatment.

Остается спорным вопрос о соответствующей тактике лечения ранней стадии рака яичников. В работе проанализированы литературные данные, с тем чтобы найти ответы на следующие вопросы: как провести раннюю диагностику рака яичников и снизить до минимума воздействие терапии, чтобы предотвратить развитие осложнений и токсичность лечения, не нанося вреда здоровью и повысить эффективность лечения. Показано, что применение современных неинвазивных методов исследования (позитронной эмиссионной томографии, магнитной резонансной томографии) существенно улучшает диагностические возможности оценки распространения опухоли. Данный факт, равно как и более глубокия знания о прогностических факторах, позволит нам оптимизировать и индивидуализировать процесс лечения пациента.

Stage I—II ovarian cancerscreeningdiagnosistreatmentрак яичниковI—II стадияскринингдиагностикалечение1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Вестн РОНЦ им Н.Н. Блохина РАМН 2008;19(2 прил 1).Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Вестн РОНЦ им Н.Н. Блохина РАМН 2008;19(2 прил 1).2. Omura G.A., Brady M.F., Homesley H.D. et al. Long-term follow- up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experi- ence. J Clin Oncol 1991;9(7):1138—50. 3. Dembo A.J., Davy M., Stenwig A.E. et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75(2):263—73.Omura G.A., Brady M.F., Homesley H.D. et al. Long-term follow- up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experi- ence. J Clin Oncol 1991;9(7):1138—50. 3. Dembo A.J., Davy M., Stenwig A.E. et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75(2):263—73.4. Goff B.A., Mandel L., Drescher C.W. et al. Development of an ovarian cancer symptom index. Cancer 2007;109:221—7.Goff B.A., Mandel L., Drescher C.W. et al. Development of an ovarian cancer symptom index. Cancer 2007;109:221—7.5. NCCN Practice Guidelines in Oncology 2009. Vol. 1.NCCN Practice Guidelines in Oncology 2009. Vol. 1.6. Ozols R.F., Rubin S.C., Thomas G. et al. Epithelial ovarian cancer. In: Principles and practice of gynecologic oncology. W.J. Hoskins, C.A. Perez, R.C. Young, eds. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005. p. 919—22.Ozols R.F., Rubin S.C., Thomas G. et al. Epithelial ovarian cancer. In: Principles and practice of gynecologic oncology. W.J. Hoskins, C.A. Perez, R.C. Young, eds. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005. p. 919—22.7. Grover S., Quinn M.A., Weideman P. et al. Screening for ovarian cancerusing serum CA125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer 1995;5:291—5.Grover S., Quinn M.A., Weideman P. et al. Screening for ovarian cancerusing serum CA125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer 1995;5:291—5.8. Jacobs I.J., Skates S., Davies A.P. et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355—8.Jacobs I.J., Skates S., Davies A.P. et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355—8.9. Skates S.J., Menon U., MacDonald N. et al. Calculation of the risk of ovarian can- cer from serial CA-125 values for preclini- cal detection in postmenopausal women. J Clin Oncol 2003;21(10 suppl):206—10.Skates S.J., Menon U., MacDonald N. et al. Calculation of the risk of ovarian can- cer from serial CA-125 values for preclini- cal detection in postmenopausal women. J Clin Oncol 2003;21(10 suppl):206—10.10. Rosenthal A.N., Menon U., Jacobs I.J. Screening for ovarian cancer. Clin Obstet Gynecol 2006;49:433—47.Rosenthal A.N., Menon U., Jacobs I.J. Screening for ovarian cancer. Clin Obstet Gynecol 2006;49:433—47.11. Jacobs I.J., Skates S.J., MacDonald N. et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207—10.Jacobs I.J., Skates S.J., MacDonald N. et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207—10.12. McBee W.C., Escobar P.F., Falcone T. Which ovarian masses need intervention? Cleveland Clin J Med 2007;74(2):149—77.McBee W.C., Escobar P.F., Falcone T. Which ovarian masses need intervention? Cleveland Clin J Med 2007;74(2):149—77.13. Rulin M.C., Preston A.L. Adnexal masses in postmenopausal women. Obstet Gynecol 1987;70:578—81.Rulin M.C., Preston A.L. Adnexal masses in postmenopausal women. Obstet Gynecol 1987;70:578—81.14. Im S.S., Gordon A.N., Buttin B.M. et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35—41.Im S.S., Gordon A.N., Buttin B.M. et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35—41.15. Kurtz A.B., Tsimikas J.V., Tempany C.M. et al. Diagnosis and stag- ing of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis—report of the Radiology Diagnostic Oncology Group. Radiology 1999;212:19—27.Kurtz A.B., Tsimikas J.V., Tempany C.M. et al. Diagnosis and stag- ing of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis—report of the Radiology Diagnostic Oncology Group. Radiology 1999;212:19—27.16. Nam E., Kim Y., Kim J. et al. Diagnosis and staging of ovarian cancer: ComparativeNam E., Kim Y., Kim J. et al. Diagnosis and staging of ovarian cancer: Comparativevalues of PET/CT, Doppler US, CT, and MRI correlated with histopathologic analysis. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26(15 Suppl):5567.17. Young R.C., Decker D.G., Wharton J.T. et al. Staging laparotomy in early ovarian cancer JAMA 1983;250:3072—6.Young R.C., Decker D.G., Wharton J.T. et al. Staging laparotomy in early ovarian cancer JAMA 1983;250:3072—6.18. Piver M.S., Marchetti D.L. Potential for cure in ovarian cancer. Compr Ther 1986;12:13—20.Piver M.S., Marchetti D.L. Potential for cure in ovarian cancer. Compr Ther 1986;12:13—20.19. Минимальные клинические реко- мендации Европейского общества ме- дицинской онкологии. Под ред. С.А. Тюляндина, Н.И. Переводчико- вой, Д.А. Носова. М.: РОНЦ им.Минимальные клинические реко- мендации Европейского общества ме- дицинской онкологии. Под ред. С.А. Тюляндина, Н.И. Переводчико- вой, Д.А. Носова. М.: РОНЦ им.Н.Н. Блохина РАМН, 2007. с. 34—7.20. Faber A.N., Rose P.G. Роль хирур- гии в лечении рака яичников. J Clin Oncol 2007;1(4):331—41.Faber A.N., Rose P.G. Роль хирур- гии в лечении рака яичников. J Clin Oncol 2007;1(4):331—41.21. Zanetta G., Chiari S., Rota S. et al. Conservative surgery for stage I ovarian car- cinoma in women of childbearing age. Br J Obstet Gynaecol 1997;104(9):1030—5.Zanetta G., Chiari S., Rota S. et al. Conservative surgery for stage I ovarian car- cinoma in women of childbearing age. Br J Obstet Gynaecol 1997;104(9):1030—5.22. Cliby W.A., Aletti G.D., Wilson T.O., Podratz KC. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 2006;12.103:797—801.Cliby W.A., Aletti G.D., Wilson T.O., Podratz KC. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 2006;12.103:797—801.23. Burghardt E., Pickel H., Lahousen M., Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986;155:315—9.Burghardt E., Pickel H., Lahousen M., Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986;155:315—9.24. Maggioni A., Benedetti Panici P, Dell A.T. et al. Randomized study of sys- tematic lymphadenectomy in patients with epithelial ovarian cancer macro- scopically confined to the pelvis. Br J Cancer 2006;95:699—704.Maggioni A., Benedetti Panici P, Dell A.T. et al. Randomized study of sys- tematic lymphadenectomy in patients with epithelial ovarian cancer macro- scopically confined to the pelvis. Br J Cancer 2006;95:699—704.25. Onda T., Yoshikawa H., Yasugi T. et al. Patients with ovarian carcinoma upstaged to stage IIIc after systematic lymphadenec- tomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer 1998;83:1555—60.Onda T., Yoshikawa H., Yasugi T. et al. Patients with ovarian carcinoma upstaged to stage IIIc after systematic lymphadenec- tomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer 1998;83:1555—60.26. Hacker N.F., Valmadre S., Robertson G. Management of retroperitoneal lymph nodes in advanced ovarian cancer. J Gynecol Cancer 2008;18(Suppl 1):7—10.Hacker N.F., Valmadre S., Robertson G. Management of retroperitoneal lymph nodes in advanced ovarian cancer. J Gynecol Cancer 2008;18(Suppl 1):7—10.27. Ryan M., Stainton C., Slay tor E. et al.Aetiology and prevalence of lower limb lymphoedema following treatment for gynaecological cancer. Aust NZ Obstet Gynaecol 2003;43:148—51.Ryan M., Stainton C., Slay tor E. et al.Aetiology and prevalence of lower limb lymphoedema following treatment for gynaecological cancer. Aust NZ Obstet Gynaecol 2003;43:148—51.28. Krishnan C.S., Grant P.T., Robertson G., Hacker N.F. Lymphatic ascites following lymphadenectomy for gynaecological malignancy. Int J Gynecol Cancer 2001;11:392—6.Krishnan C.S., Grant P.T., Robertson G., Hacker N.F. Lymphatic ascites following lymphadenectomy for gynaecological malignancy. Int J Gynecol Cancer 2001;11:392—6.29. Ahmed F.Y., Wiltshaw E., Nocol B. et al. Natural history and prognosis of untreated stage I epithelial ovarian carci- noma. J Clin Oncol 1996;14(11):2968—75.Ahmed F.Y., Wiltshaw E., Nocol B. et al. Natural history and prognosis of untreated stage I epithelial ovarian carci- noma. J Clin Oncol 1996;14(11):2968—75.30. Robert C. Young early-stage ovarian cancer: to treat or not to treat. J National Cancer Inst 2003;95(2).Robert C. Young early-stage ovarian cancer: to treat or not to treat. J National Cancer Inst 2003;95(2).31. Hreshchyshyn M.M., Park R.C., Blessing J.A. et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 1980;138:139—45.Hreshchyshyn M.M., Park R.C., Blessing J.A. et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 1980;138:139—45.32. Young R.C., Walton L.A., Ellenberg S.S. et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990;322:1021—7.Young R.C., Walton L.A., Ellenberg S.S. et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990;322:1021—7.33. Vergote I.B., Vergote-De Vos L.N., Abeler V.M. et. al. Randomized trial comparing cisplatin with radioactive phosphorus or whole abdomen irradia- tion as adjuvant treatment of ovarian can- cer. Cancer 1992;69:741—9.Vergote I.B., Vergote-De Vos L.N., Abeler V.M. et. al. Randomized trial comparing cisplatin with radioactive phosphorus or whole abdomen irradia- tion as adjuvant treatment of ovarian can- cer. Cancer 1992;69:741—9.34. Bolis G., Colombo N., Pecorelli S. et al. G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 1995;6:887—93.Bolis G., Colombo N., Pecorelli S. et al. G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 1995;6:887—93.35. Young R.C., Brady M.F., Nieberg R.K. et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin — a gynecologic oncology group study. J Clin Oncol 2003;21:4350—5.Young R.C., Brady M.F., Nieberg R.K. et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin — a gynecologic oncology group study. J Clin Oncol 2003;21:4350—5.36. Trimbos J.B., Parmar M. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95(2):105—12.Trimbos J.B., Parmar M. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95(2):105—12.37. Trimbos J.B, Vergote I., Bolis G., Vermorken J. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003;95(2):113—25.Trimbos J.B, Vergote I., Bolis G., Vermorken J. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003;95(2):113—25.38. Vergote I., De Brabander J., Fyles A. et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176—82.Vergote I., De Brabander J., Fyles A. et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176—82.39. Kolomainen D.F., A’Hern R., Coxon F.Y. et al. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol 2003;21(16):3113—8.Kolomainen D.F., A’Hern R., Coxon F.Y. et al. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol 2003;21(16):3113—8.40. Bell J., Brady M.F., Young R.C. et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and pacli- taxel in early stage epithelial ovarian carci- noma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102(3):432—9.Bell J., Brady M.F., Young R.C. et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and pacli- taxel in early stage epithelial ovarian carci- noma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102(3):432—9.41. Winter-Roach B.A., Kitchener H.C., Dickinson H.O. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD004706. DOI: 10.1002/14651858.CD004706.pub2.Winter-Roach B.A., Kitchener H.C., Dickinson H.O. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD004706. DOI: 10.1002/14651858.CD004706.pub2.